Flagship product from Honeycomb Biotechnologies advances single-cell profiling by enabling scientists to capture, store and study fragile cell types.

Orbit, a new business accommodation space hosted by Durham University, has opened a new facility in NETPark, one of the UK’s leading science and technology parks.

Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).

Awakn Life Sciences Corp. has announced that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.

Origin Therapeutics Holdings Inc. an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.

Noldus Information Technology is seeking proposals from North American researchers from all disciplines of behavioral science research.

AMSBIO reports upon a publication that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.

Uniqsis makes flow chemistry accessible to everyone, while at the same time catering for multi-step and automated reactions sequences, through the availability of an expanding suite of affordable 'plug and play' reactor modules.

PhoreMost Ltd. has announced it has appointed Dr Christian Dillon as Vice President of Biology.

MEGIN is pleased to announce the acquisition of a TRIUX™ neo by The Centre For Cognitive Neuroimaging at the Institute for Neuroscience and Psychology at the University of Glasgow. This research facility will continue its role as the only MEG site in Scotland, continuously supporting neuroimaging related research.